Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
ECB Calls for Monitoring and Possible Regulation of AI in Finance 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Subaru and Toyota Collaborate on 3 New Electric SUVs, Citing ‘Huge Risk’ of Solo EVs 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
Nongshim Eyes New Domestic Plant to Fuel Global Ramyeon Demand 
US Airlines Sue Over New Fee Disclosure Rule 
How supermarkets are changing their branding to make you think they’re cheaper 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
First Look: Tesla Cybertruck's New Tactical Grey Interior Spotted in Forum Images 
BOTHELL, Wash., April 12, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced public offering of common stock, including 806,451 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. Gross proceeds from the offering of an aggregate of 6,182,795 shares at a public offering price of $23.25 per share, before underwriting discounts and commissions and offering expenses, were approximately $143.8 million.
J.P. Morgan Securities LLC, Leerink Partners LLC and Wells Fargo Securities, LLC acted as joint book-running managers for the offering.
A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was effective on filing on June 2, 2015. A prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at 1-866-803-9204, or by email at [email protected]; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by phone at 1-800-808-7525 ext. 6142, or by email at [email protected]; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by phone at 1-800-326-5897, or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contacts: David Schull or Lena Evans Russo Partners (212) 845-4271 (212) 845-4262 [email protected] [email protected] Investor Relations Contacts: David Walsey Alder BioPharmaceuticals, Inc. (425) 408-8032 [email protected]
